Synaptogenix, Inc. SNPX

Overview

Synaptogenix, Inc. is a biopharmaceutical company engaged in the development of innovative therapies for neurodegenerative diseases, with a primary focus on Alzheimer's disease. Incorporated in 2012 and based in New York, New York, Synaptogenix is dedicated to advancing its product candidates through pre-clinical and clinical development stages. The company's research and development efforts are centered on a drug candidate known as Bryostatin-1, which shows promise for not only Alzheimer's disease but potentially for a range of other cognitive diseases and dysfunctions.

Products and Services

• Bryostatin-1 for Alzheimer's Disease

  Synaptogenix's flagship product, Bryostatin-1, is under development as a treatment for Alzheimer's disease. This drug candidate is based on extensive research and is currently in various stages of clinical development. Bryostatin-1 has been shown to have potential in restoring synaptic density and function, which are often diminished in Alzheimer's patients.

• Bryostatin-1 for Other Neurodegenerative or Cognitive Diseases and Dysfunctions

  Beyond Alzheimer's disease, Synaptogenix is exploring the therapeutic applications of Bryostatin-1 for a variety of other neurodegenerative or cognitive disorders. This includes fragile X syndrome, multiple sclerosis, and Niemann-Pick type C disease. The versatility of Bryostatin-1 demonstrates Synaptogenix's commitment to addressing the broader spectrum of cognitive diseases and dysfunctions, potentially offering hope to patients with conditions that currently have limited treatment options.